Navigation Links
Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results
Date:2/14/2008

ins were 25.4% for the first six months of 2008 compared to 28% for the first six months of 2007. Net income was $3.2 million for the six months ended December 31, 2007, an increase of 65% from the same period in 2006.

Balance Sheet and Cash Flow

The Company had a current ratio of 2.6 to 1 and $4.6 million in cash and accounts receivable on December 31, 2007. The Company reported $1.3 million in short-term notes and no long-term debt. For the first six months of 2008, the Company provided $1.75 million in cash for operations, the main driver for cash flow was net income of $3.2 million and a significant increase in revenues. On January 28, 2008, subsequent to the end of their second quarter, Tianyin announced a private placement of $15.2 million.

"I would like to thank all of the investors who participated in our recent private placement. This capital will be used to significantly expand our production capacity during the coming six to twelve months to meet demand supported by the continued growth in expenditures per capita on Traditional Chinese Medicines (TCMs) and government support for additional cost reimbursement of our products," stated Jiang. "TCM's have been deeply ingrained in Chinese culture for thousands of years and long been perceived by many Chinese to be both safe and efficacious. Strong government support to include more TCM's to the list of medicines subject to reimbursement in the National Medicine Catalog, along with the Chinese SFDA's plan to release more product approvals will be advantageous for the future growth prospects for our large pipeline of new products."

Conference Call

The Company will host a conference call to discuss the 2008 second quarter financial results on Thursday, February 14, 2008 at 4:15 p.m. EST. Interested participants should call 800-762-8908 within the United States, or US +1-480- 629-1990 if calling internationally. It is advisable to dial in approximately 5-10 minutes prior to the 4
'/>"/>

SOURCE Tianyin Pharmaceutical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Tianyin Pharmaceutical, Inc. to Host 2008 Second Quarter Earnings Conference Call on Thursday, February 14, 2008 at 4:15 p.m. EST
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... December 16, 2014 “Never say, ... Philipps- Universität Marburg’s Department of Physics, advises young ... the newly released SPIE Women in Optics ... too shy to ask questions.” , In the ... and mathematics) occupations ranging from university professor and ...
(Date:12/17/2014)... December 17, 2014 Xeno Diagnostics ... following its most recent COLA inspection. Xeno has ... a national healthcare accreditation organization. Accreditation is earned ... quality in day-to-day operations, demonstrate continued accuracy in ... rigorous on-site laboratory survey. , While ...
(Date:12/17/2014)... Md. , Dec. 17, 2014 CASI ... company dedicated to the acquisition, development and commercialization of ... for the global market with a primary commercial focus ... it has been granted a Type C meeting with ... the meeting will be held in February 2015.  During ...
(Date:12/15/2014)... DIEGO , Dec. 15, 2014 ... three-dimensional biology company focused on delivering breakthrough 3D ... the industry and collaborators of its exVive3D TM ... made widely available in full commercial release on ... the field, resulting in several awards for innovation. ...
Breaking Biology Technology:Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 3Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 3
... Chilcott,Limited (Nasdaq: WCRX ) announced today that LEO ... from the U.S. Patent and,Trademark Office (the "USPTO"). In ... Patent No. 6,753,013 (the "013 Patent") in,response to a ... TACLONEX,and certain of LEO,s products in development. Warner Chilcott ...
... 17 Diageo (NYSE: DEO ),the world,s leading ... sponsorship of a physician,s training program in screening and ... State of,New York (MSSNY). The program, funded entirely ... better prepare physicians to address and assess issues,related to ...
... LMNX ) today announced that management will present ... held September,17-20, 2007, at the St. Regis Hotel in ... Balthrop, president and chief,executive officer, will begin at 11:00 ... 18, 2007. The presentation will be webcast live,and may ...
Cached Biology Technology:Warner Chilcott Announces New Information in USPTO Reexamination of Taclonex Patent 2Warner Chilcott Announces New Information in USPTO Reexamination of Taclonex Patent 3Diageo Sponsors Medical Society of the State of New York's Physicians Training Program 2Diageo Sponsors Medical Society of the State of New York's Physicians Training Program 3Luminex Corporation to Present at ThinkEquity Partners Investor Conference 2
(Date:12/10/2014)... Dec. 08, 2014 Research and Markets ... of the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration ... as rural banking and upgradation of the driver,s ... in the market. Besides the aforementioned projects, biometrics ...
(Date:12/4/2014)... , Dec. 3, 2014  Crossmatch™, a ... announced that its DigitalPersona ® Pro Enterprise ... have been deployed throughout First Bank branch locations ... South Carolina and Virginia. First Bank, ... Southern Pines, North Carolina , selected ...
(Date:11/21/2014)... -- Earlier this year Donald Spector , Chairman of ... the most prolific inventors in the world, got a ... to third party agencies. Spector envisioned this technology even ... earliest known patents in this area. Now major technology ... care, elder care and hospital applications. This technology has ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... (BMC) and Boston University School of Public Health (BUSPH) ... at home are less likely to receive colorectal cancer ... English at home. The findings, which currently appear on-line ... patient-provider language barriers play a role in health-care disparities, ...
... to Secretary Kathleen Sebelius at the U.S. Department of ... called out 10 specific challenges to proposed modifications to ... on behalf of its membership of 4,000 informatics professionals, ... of Proposed Rulemaking (NPRM) on HIPAA modifications, along with ...
... frigatebird may be the least likely animal on the ... turns out the Galapagos population of this tropical seabird ... new conservation status, according to a paper by researchers ... Museum of Natural History and the University of Missouri-St. ...
Cached Biology News:Study finds language barriers may play role in health care disparities 2AMIA cites concerns about proposed HIPAA modifications 2AMIA cites concerns about proposed HIPAA modifications 3AMIA cites concerns about proposed HIPAA modifications 4Smithsonian researchers find differences between Galapagos and mainland frigatebirds 2
BD Falcon 850 cm Smooth-surface TufRol Roller Bottle, tissue-culture treated polystyrene, blow-molded one-piece design, with easy on/off non-vented cap. (2/sp, 20/ca) Packaging: 2 / pack, 20 /...
... Display Vector is specifically designed to target ... of Saccharomyces cerevisiae. Displayed proteins can be ... known or putative ligands. pYD1 uses the ... two domains, Aga1 and Aga2, to display ...
... are used for heterologous protein expression in the ... S2 cell line was derived from a primary ... Drosophila melanogaster embryos (1). This versatile ... CO2 and is easily adapted to suspension culture. ...
ACS Reagent Grade C 19 H 14 O 5 S Formula Weight: 354.38 PRODUCT SPECIFICATIONS Form: Rust/red crystalline powder Clarity of Solution: Passes test Visual Transition Interval: pH 6.8 - Yellow pH 8.2...
Biology Products: